Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Choong‐kun Lee et al.|NEJM Evidence|2022Cited by 1.1k
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialMasatoshi Kudo, Yasuaki Arai, Kazuomi Ueshima et al.|Gut|2019Cited by 720
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyHideki Ueno, Masao Tanaka, Tatsuya Ioka et al.|Journal of Clinical Oncology|2013Cited by 632
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hiroya Taniguchi et al.|Nature Medicine|2020Cited by 366
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialChigusa Morizane, Junji Furuse, Takuji Okusaka et al.|Annals of Oncology|2019Cited by 333